¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º #]^M/y h  
vVsaGW   
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ _p9 _Pg8  
&b2@+/ F  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) vB5mOXGNq  
JxM32?Rm*w  
1. ICAM-1 2+R]q35-  
PMvm4<  
2. interleukin 12(IL-12) H ;Gs0Qi;  
v^[!NygShs  
3. tumor infiltrating lymphocyte HPo><u  
Q2Uk0:M  
4. TCR/CD3 complex {`Mb),G  
Uf ?+oc'{  
5. hematopoietin receptor family eq9qE^[Z&  
6QPT  
6. individual idiotype(IdI) jDj=a->e^  
EFu>  
7. integrin X6?Gxf,  
t6)R 37  
8. colony-stimulatory factor (CSF) PX?^v8wlqL  
i A'p!l |P  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Ct3+ga$  
-YipPo"a  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? CdtwR0  
;BHIss7  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ |I.5]r-EK  
(YYwn@NGj  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠItAC=/(d  
u(`7F(R  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ sq8O+AWl  
A=*6|1w;  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) `_J>R  
g+C~}M_7  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ %XXjQ5p  
SNHAL F  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) j ?! /#'  
gLbTZM4i  
3. immunoglobulin superfamily (IgSF) 9a'}j#mJo  
OoZv\"}!_  
4. selectin :QMpp}G  
8%b-.O:_$  
5. anti-idiotypic antibody (¦ÁId) A5G@u}YS5  
t & 5s.  
6. major histocompatibility complex(MHC) &Hl w2^  
+n|@'= ]  
7. immunotolerance }&EdA;/o_  
* a VT  
8. biological reponse modifier(BRM) 1EliR uJ  
O+~@ S~  
9. immune reponse gene (Ir gene) tz%H1 `  
,u.A[{@py  
10. reshaped antibody (or reconstituted antibody) Acb %)Y  
>i2WYT  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© kyD*b3MN  
k,r}X:<6jz  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ VS5D)5w#  
kg$w<C@#"  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? ,{#Li  
?a~#`<  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ PkF'#W%  
z*/}rk4i  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? ^ }|$_  
stOD5yi  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ 12bztlv  
C)ebZ 3  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? zUJPINDb  
Jrx]/CM  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ = /=?l  
2S-z$Bi}]  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ _RG2I)P  
Xxs0N_va&  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? oMF[<Xf  
c.;<+dYsm*  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ @}A3ie'w  
-W)8Z.  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: V(6Ql j7  
w;V+)r?w  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: #(r1b'jfP  
r%` |kN  
ÃâÒßѧ >W=^>8u  
:&$ WW v  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 6 G?7>M  
=~{W;VZt'  
1. CD8  H r;\}  
d{RMX<;G  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) Cg%}=  
rJc=&'{&)N  
3. immunoglobulin fold(Ig fold) hbTJXP~~?  
3 bl l9Ey  
4. cadherin (Ca-dependent cell adhesion moleculers) '=>l& ;  
jo[U6t+pj7  
5. idiotype-anti-idiotypic antibody immune network theory ' 8UhYwyr  
.jbT+hhM  
6. HLA class II antigen ZTK)N  
5*r5?n e  
7. complementarity-determining region (CDR) {#}?-X  
<+e&E9;>6  
8. perforin(or pore-forming protein ,PFP) &W-1W99auE  
;F\sMf{  
9. high affinity IL-2 receptor ? ]hS^&  
>7nOR  
10. artificial active immunization >Mk#19j[/  
t[b@P<F  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© wVtBH _>  
WO"<s{v  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ?4MZT5 .  
2U`g[1  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 2+qU9[kd|  
t gHXIr}3  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ #EX NSr  
&=hkB9 ;  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ O (YvE  
R)BH:wg"  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ 5{O9<~,  
+]jJ:V  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? 7DCu#Y[  
8VR! Y0`e  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 3[}w#n1  
Q804_F F#  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ Q[UYNQ0w  
DYaOlT(rE  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ~ U`|+ 5  
l\1_v7s  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ Lt\=E8&rh  
} {<L<  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© uT 2w2A;  
OIdoe0JR:O  
1. immunoglobulin gene rearrangement NJ$c0CNy  
tboc7Hor4  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) A<<Bm M.%  
rWD*DmY@"  
3. flow cytometry(FCM) P_N i 5s)  
k#pNk7;MZ  
4. carrier effect xr).ZswQ  
h$rk]UM/Q  
5. positive selection of T lymphocytes in thymus mZ}C)&,m2  
Nr:%yvk%s  
6. mouse TH1(Th1) and TH2(Th2) subsets e.? ;mD  
Xwt}WSdF`k  
7. perforin (pore-forming protein ,PFP) Q2nqA1sRk  
UJhUb)}^  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) 31=v US  
BhCOT+i;c  
9. SH-2(src-homology region 2) 2L|)uCb  
5;Q9Z1 `  
10. Ab2¦Â (internal image) & 24$*Oe  
J\c\Ar :  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© .rs\%M|X  
HA0Rv#p  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? YH/3N(],  
R"V^% z;8o  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? 35 PIfq m  
,R2;oF_  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠBNpc-O~  
L|N[.V9  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ ^U[yk'!Y  
8lfKlXR78  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ4NxI:d$&*  
.}x:yKyi@  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) )9'Zb`n  
*>8Y/3Y\B  
ÃâÒßѧרҵ£º fNaboNj[  
_ !H8j/b  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ unN=yeut  
x !QA* M  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? G0&'B6I>  
Q3|I.I e  
´«È¾²¡Ñ§×¨Òµ£º 'ghwc:Og|%  
Sxg&73;ZV  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ :Co+haW  
$1b x\  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ A!.* eIV|  
qbu5aK}+  
Ïû»¯×¨Òµ£º /{HK0fd  
k*Vf2O3${  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ XX|wle1Kg  
#uillSV  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? '1te(+;e@  
~u+|NtF  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ |cd=7[B  
[$P.ek<  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ;|H(_J=6k  
Y%A KN  
1. Fas(CD95)/FasL 95X!{\  
*&sXC@^@^  
2. common chain of cytokine receptor Imm|5-qJ  
J0a#QvX!  
3 . TCR/CD3 complex Mh;rhQ  
`p{,C`g,R  
4. negaive selection of thymocytes j~:N8(=  
RFzMah?Q=j  
5. artificial active immune kx_PMpc  
Qpaan  
6. anti-idiotypic jYi{[* *  
'YUx&F cM  
7. IgSF <<:a >)6\  
=gb(<`{ >  
8. Integrin ":upo/xN  
 T24?1  
9. chemokine *)H&n>"e  
OlI{VszR  
10. B7/CD28 WCPl}7>  
!NfN16  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© qn4jy6  
7 /$s!pV  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ m;]glAtt  
wRi` L7  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ SWGD(]}uz  
zxr|:KC ?&  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ wWNHZ v&  
z nc'  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ &@MiR8  
*1 [v08?!  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ s s*% 3<  
eHjn<@  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ xX ktMlI  
= NHzh!  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© :z! N_]t  
Evn=3Tw  
1. B7/CD28 ! awfxH0  
.#] V5g,  
2. Th1 subset oVLgHB\zL  
=a<};X  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© BWct0=  
. .|>|X4  
4. antibody affinity maturation AIvIQ$6}  
{i7Wp$ug  
5. AP-1 Qw ukhD7  
gqje]Zc<  
6. single chain variable fragment£¨ScFv£© 7X$[E*kd  
DUk&`BSJ  
7. NK cell receptor }T?0/N3y&  
GN4'LU  
8. Zinkernagel-Doherty phenomenon hy"O_Le  
_JZw d9K  
9. Ig fold +h }>UK\  
2Qqk?;^ 1  
10. CD40/CD40L UvSvgDMl  
gNdEPaaFI  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© RnN]m!"5  
9y(75Bn9  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ p`jkyi  
2 g elmQnc  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ B&~#.<23:  
[X'XxYbZ  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ %T hY6y(  
b]'Uv8fbF  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ Q= DP# 9&  
@)A)cBv#  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ Zl69d4vG  
d{cd+An  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ 3BuG_ild  
Wgx Gx`Y)  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ :a M ZJm  
x;&01@m.  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© @6eM{3E.  
5OUGln5  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© f}JiYZ  
D# ZzhHHP  
1.Co-stimulators (or co-stimulating molecules) n[~kcF  
gnjh=anVX1  
2.NK-kB RRW/.y  
Aofk<O!M  
3.Immunoglobulin superfamily ]JQ7x[  
ldd|"[Ds  
4.antigen-presenting cell (APC) Tm!pAD  
CH!>RRF  
5.death domain x=1Iuc;&3  
/NFk@8<?  
6.CCR and CXCR bXVH7Fy  
pKe K6K\8  
7.Lectin (or mitogen) C`qo  
?T]` X  
8.Clusters of differentiation, CD) Q"o* \I  
&J>XKO nl  
9.B7 family ,8=`Y9#  
]q#w97BxiJ  
10.Cytotoxic T lymphocyte, CTL) 9|kc$+(+6  
8>U{>]WG  
11.IL-15 and IL-15 receptor (IL-15R) ORVFp]gG  
(T290a9y>  
12.MHC restriction R,+Pcn$ws  
1!(Og~#(  
13.Affinity-chromatography 9%{V?r]k  
]2:w?+T  
14.Cyctosprin A, CsA 4Ss4jUj  
r;>2L'  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) %Aqt0e  
+c7e[hz  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© jN3K= MA  
}PC_qQF  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 }s9eRmJs  
Ff eX;pi  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ yj:<3_-C*  
xE$>;30b_  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ y cT@ D/  
g1!ek  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© V4["+ Y  
]'.D@vFGO  
ÃâÒßѧרҵ£º =&_Y=>rA]0  
.RazjXAY  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ (BT{\|,V_m  
B;vpG?s{9  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ xYLTz8g=  
9Sb[5_Q  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ n< )gS7  
)yl;i  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) G?,b51"  
?hFG+`"W  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) Il 4R R  
["u:_2!4P  
1. ADCC(antibody dependent cell-mediated cytotoxicity) VYo2m  
m=4hi( g  
2. »·æß¾úËØ(cyclosporin) x/d(" Bb  
O0Pb"ou_h.  
3. KIR(killer cell inhibitory receptor) %a=^T?8  
*SmR|Qy  
4. HLDA(human leucocyte differentiation antigen) mS9ITe M  
"9v4'"  
5. Interleukin 18(IL-18) `9`T,uJe  
q; ?Kmk  
6. ÕûºÏËØ(integrin) l+r3|b  
r.ib"W#4  
7. Fas/FasL H/^t]bg,  
/D>G4PP<  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) ]kir@NMv>  
2[X\*"MQ2  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) DX(!G a  
-}CMNh   
10. Th1/Th2 [r0`D^ *=  
|@Ze{\  
11. »ùÒòÒßÃç(DNAÒßÃç) /=[hRn@)A  
gkFw=Cd  
12. chemokines and chemokine receptor uwc@~=;  
c2Yrg@) [  
13. ÃâÒßÄÍÊÜ mO0}Go8  
 _W  
14. ¹²´Ì¼¤·Ö×Ó /2x@Z>  
> zV  
15. ËÀÍö½á¹¹Óò(death domain) ho%G  
0gsRBy  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) K)#6&\0tT  
6){nu rDBG  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? EQVa8xt/C  
$Ned1@%[  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠmCSt.n~  
YM&i  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î t[p/65L>8  
P*/ig0_fM  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ : U,- v  
cuh Z_l  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå 4l@aga  
Q#lFt,.y  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ ~Z}DN*S  
42=/$V  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) w"q^8"j!  
3/Dis) v8  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ ;~Gez;AhK  
^!Tq(t5V  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ =kb/4eRg  
"4L_BJZ  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»